

Cytiva expands MabSelect resin portfolio with new solutions for cost-effective and scalable mAb purification

03 April 2025 | News

Next-generation MabSelect SuRe™ 70 and Prisma™ X resins address the growing complexity of mAb and biosimilar development, offering tailored, sustainable options across all stages of drug manufacturing.



Cytiva, a global leader in life sciences, has expanded its industry-leading MabSelect™ protein A resin portfolio with the launch of MabSelect SuRe™ 70 and MabSelect Prisma™ X resins. Designed to address the diverse needs of monoclonal antibody (mAb) and biosimilar production, these next-generation resins set new standards in affordability, productivity, and sustainability.

With the continued growth of the mAb market and rapid acceleration in biosimilar development, biomanufacturers require more tailored, cost-efficient solutions that can adapt across different drug development stages. Recognizing this, Cytiva's expanded resin offerings provide scalable options without compromising on quality or performance.

"The different stages of drug development require different purification needs," said Sofie Stille, Vice President and General Manager, Resins and Technologies, Cytiva. "As more molecules are advancing to the clinic, we wanted to provide our customers with innovative and cost-effective options regardless of stage. These new resins offer affordability without sacrificing quality."

Supporting the Full Spectrum of mAb Development

- MabSelect SuRe™ 70: Tailored for clinical development, this resin features high dynamic binding capacity (DBC) combined with cost-efficiency, making it ideal for early-stage programs where batch numbers are limited but quality and performance are essential.
- MabSelect PrismA™ X: Engineered for robustness and scalability in commercial manufacturing, this resin provides the highest DBC of all MabSelect resins and superior durability, enabling high-performance mAb capture with enhanced productivity.

Both resins are based on agarose, a renewable raw material, in line with Cytiva's commitment to sustainable biomanufacturing. Cytiva owns its agarose production facility in Denmark and operates its resin manufacturing in Sweden, ensuring a secure, localized supply chain. The company has also bolstered supply chain resiliency with the renovation of a second manufacturing site in Muskegon, Michigan, USA, now undergoing tech transfer.

Flexibility Meets Sustainability

Cytiva's expanded portfolio empowers customers to reduce manufacturing costs, increase operational agility, and align with sustainability goals—whether in preclinical trials or commercial-scale production.

“At whatever stage or scale a customer is at, we can offer solutions that fit—whether that’s based on speed, performance, or affordability—all sustainably designed,” added Stille.

As the protein purification landscape evolves, Cytiva continues to support global biopharma innovators with reliable, innovative, and sustainable solutions that accelerate drug development and enable access to life-changing therapies.